Matsunari I, Haas F, Nguyen N T, Reidel G, Wolf I, Senekowitsch-Schmidtke R, Stöcklin G, Schwaiger M
Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar, Germany.
J Nucl Med. 2001 May;42(5):818-23.
Although there are several 99mTc perfusion tracers introduced for clinical use, there are no data available directly comparing these tracers with microsphere-determined flow. The aim of this study was to compare the myocardial retention of sestamibi, tetrofosmin, and Q12 in a porcine model.
We used a pig model with (n = 6) or without (n = 3) coronary occlusion. Each pig received a simultaneous injection of sestamibi and either tetrofosmin (group 1, n = 5) or Q12 (group 2, n = 4) labeled with either 99mTc or 95mTc (physical half-life, 61 d; photon energy, 204 keV) during pharmacologic vasodilation. Absolute myocardial retention of each tracer was calculated from the myocardial tracer activity and arterial input function.
The plot of all three tracers versus flow achieved a plateau at a higher flow range. However, sestamibi showed a higher mean retention than either tetrofosmin (group 1, 0.27 +/- 0.11 vs. 0.16 +/- 0.06 mL/g/min, respectively; P < 0.01) or Q12 (group 2, 0.32 +/- 0.13 vs. 0.09 +/- 0.03 mL/g/min, respectively; P < 0.01). Furthermore, when a linear regression analysis was performed to assess the relationship between retention and microsphere-determined flow, sestamibi showed a greater increment in retention than did tetrofosmin or Q12.
Although all of the tracers showed a nonlinear increase in retention as flow increased, sestamibi may display more favorable characteristics as a flow tracer in the porcine heart.
尽管有几种99mTc灌注示踪剂已引入临床使用,但尚无直接比较这些示踪剂与微球测定流量的数据。本研究的目的是在猪模型中比较 sestamibi、替曲膦和Q12的心肌滞留情况。
我们使用了有(n = 6)或无(n = 3)冠状动脉闭塞的猪模型。在药物性血管扩张期间,每只猪同时注射用99mTc或95mTc(物理半衰期,61天;光子能量,204 keV)标记的sestamibi和替曲膦(第1组,n = 5)或Q12(第2组,n = 4)。根据心肌示踪剂活性和动脉输入函数计算每种示踪剂的绝对心肌滞留量。
所有三种示踪剂与流量的关系图在较高流量范围内达到平台期。然而,sestamibi的平均滞留量高于替曲膦(第1组,分别为0.27±0.11 vs. 0.16±0.06 mL/g/min;P < 0.01)或Q12(第2组,分别为0.32±0.13 vs. 0.09±0.03 mL/g/min;P < 0.01)。此外,当进行线性回归分析以评估滞留与微球测定流量之间的关系时,sestamibi的滞留量增加幅度大于替曲膦或Q12。
尽管所有示踪剂的滞留量均随流量增加呈非线性增加,但sestamibi作为猪心脏流量示踪剂可能表现出更有利的特性。